培美曲塞联合顺铂治疗非小细胞肺癌临床分析

Clinical Analysis of Pemetrexed Combined with Cisplatin in the Treatment of Non-small Cell Lung Cancer

目的探析培美曲塞联合顺铂治疗非小细胞肺癌临床效果及安全性。方法方便选取该院2013年1月—2017年4月期间收治的62例非小细胞肺癌患者,通过患者知情同意将其随机分为研究组和对照组,各为31例,对照组采取吉西他滨联合顺铂治疗,研究组采取培美曲塞联合顺铂治疗,比较两组治疗后的临床有效率、不良反应情况等。结果研究组治疗后的有效率为32.26%,与对照组12.90%比较差异有统计学意义(P<0.05);研究组治疗后的疾病控制率为87.10%,与对照组61.29%比较差异有统计学意义(P<0.05);治疗组恶心呕吐80.66%、白细胞下降83.87%、肝功能损害25.81%、肾功能损害22.58%、感觉神经异常9.68%与对照组比较差异无统计学意义(P>0.05)。结论培美曲塞联合顺铂治疗非小细胞肺癌临床效果确切,优于吉西他滨联合顺铂,安全性好,具有协同加强作用,值得临床推广使用。

Objective This paper tries to investigate the clinical effect and safety of pemetrexed and cisplatin in the treatment of non-small cell lung cancer. Methods 62 patients with non-small cell lung cancer treated in this hospital from January 2013 to April 2017 were convenient selected and were randomly divided into the study group and the control group with 31 cases in each group. The control group was treated with gemcitabine cisplatin treatment, the study group took pemetrexed combined with cisplatin treatment, and then the clinical efficiency, adverse reactions and other situations of the two groups after treatment were compared. Results The effective rate was 32.26% in the study group and 12.90% in the control group. There was significant difference between the two groups（P 0.05）. The control rate of the study group was87.10% and 61.29% in the control group, with significant difference（P〈0.05）. There were no significant differences between the treatment group and the control group in nausea and vomiting of 80.66%, white blood cells decrease of 83.87%, liver function damage of 25.81%, renal dysfunction of 22.58%, sensory nerve abnormalities of 9.68% in the treatment group, without significant difference（P〈0.05）. Conclusion Pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer is more effective than gemcitabine combined with cisplatin, which is safe and has a synergistic effect. It is worth popularization.